Strategic partnerships Recent and notable partnerships with Boehringer Ingelheim to accelerate CKD and related conditions present a clear entry point for co-development or licensing discussions. Leverage their interest to position Rectify as a complementary tech driver for kidney disease programs and rare disease targets.

Platform value Rectify’s Positive Functional Modulators PFMs offer a novel mechanism to restore membrane protein function, suggesting cross-indication potential across liver, cardio-renal-metabolic, and neurodegenerative diseases. Propose expansion conversations around additional targets and pipeline synergy with existing pharma portfolios.

Regulatory-readiness With preclinical proof of concept presented and ongoing clinical candidate progression, there is momentum for discussions around divestiture, milestone-based licensing, or strategic funding that accelerates IND/early-stage trials in collaboration with larger partners seeking early asset access.

Clinical readiness Active engagement in liver disease forums and recent conference visibility indicate a credible data narrative. Use these signals to propose advisory collaboration, access to datasets, or joint feasibility studies to de-risk potential co-development opportunities.

Funding leverage A substantial $100M funding round and modest current revenue suggest room for strategic financing conversations, such as milestone-based collaborations, translational research partnerships, or grant-supported studies to scale development and expand the PFMs platform into additional indications.